Skip to main content
Equibles
MLAB logo

MLAB · Mesa Laboratories Inc /Co/ · Metrics

Track MLAB — free

Use MLAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MLAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$125.90 +2.60 (+2.10%)
Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 20% of revenue

One customer — 20% of revenue (fiscal 2026)

“In our Clinical Genomics division, a significant portion of revenues is generated from ongoing purchases by a relatively small number of established customers, with a single customer accounting for approximately 20% of the division's revenues in fiscal 2026.”
View the 10-K filed Jun 3, 2026
Market Cap
$690.00M
Shares
5.60M
Volume · Oct 20 77.23K Avg daily vol (3M) 133.1K

MLAB metrics

115 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$123.31
Market cap
$690.00M

Price action

20 metrics
Price change (1W)
-3.7%
Price change (30D)
-6.5%
Price change (3M)
+27.6%
Price change (6M)
+17.6%
Price change (YTD)
+57.1%
Price change (1Y)
+68.7%
Trailing year
Price change (5Y)
-60.2%
52-week high
$142.23
52-week low
$70.60
Change from 52-week high
-13.3%
Change from 52-week low
+74.7%
Annualized volatility
53.3%
Annualized volatility (3M)
48.1%
Beta
1.3
RSI (14D)
44.0
Price vs SMA 50
-1.5%
Price vs SMA 200
+20.7%
Avg volume (3M)
133,995
Relative volume
0.5
Average dollar volume
$15.95M

Company

3 metrics
Sector
Technology
Industry
Scientific & Technical Instruments
Shares outstanding
5.60M

Valuation

12 metrics
P / E (TTM)
145.1
Trailing earnings · reciprocal yield 0.7%
PEG ratio
—
EV / revenue
2.9×
reciprocal yield 34.6%
EV / EBITDA
—
EV / EBIT
32.1×
reciprocal yield 3.1%
P / sales
2.7×
reciprocal yield 36.4%
P / book
3.6
reciprocal yield 27.5%
FCF yield
7.7%
TTM · current market cap
Buyback yield
0.0%
P / FCF
13.0
reciprocal yield 7.7%
P / operating cash flow
12.3
reciprocal yield 8.1%
Earnings yield
0.7%

Historical valuation

8 metrics
P / E historical average (3Y)
223.0×
reciprocal yield 0.4%
P / E historical average (5Y)
323.6×
reciprocal yield 0.3%
EV / revenue historical average (3Y)
2.6×
reciprocal yield 38.7%
EV / revenue historical average (5Y)
4.3×
reciprocal yield 23.2%
EV / EBIT historical average (3Y)
54.6×
reciprocal yield 1.8%
EV / EBIT historical average (5Y)
135.0×
reciprocal yield 0.7%
EV / EBITDA historical average (3Y)
39.1×
reciprocal yield 2.6%
EV / EBITDA historical average (5Y)
43.8×
reciprocal yield 2.3%

Dividends & buybacks

7 metrics
Dividend yield
0.5%
Trailing 12 months
Payout ratio
73.6%
Shareholder yield
—
Dividend / share (TTM)
$0.64
Dividend growth YoY
+0.0%
Dividend growth streak
0
Last ex-dividend
2026-08-31

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
64.2%
Operating margin
9.0%
Trailing 12 months
Net margin
1.9%
Gross profit (TTM)
$160.34M
Operating profit (TTM)
$22.48M
Net income (TTM)
$4.80M
Trailing 12 months
Diluted EPS (TTM)
$0.85
FCF margin
21.2%
Effective tax rate
48.7%

Per share

11 metrics
Revenue per diluted share (TTM)
$44.49
Gross profit per diluted share (TTM)
$28.56
Operating profit per diluted share (TTM)
$4.00
EBITDA per diluted share (TTM)
$6.87
Net income per diluted share (TTM)
$0.85
Operating cash flow per diluted share (TTM)
$9.90
Free cash flow per diluted share (TTM)
$9.40
Capital expenditures per diluted share (TTM)
$0.50
R&D per diluted share (TTM)
$3.57
Stock compensation per diluted share (TTM)
$2.92
Book value per share
$33.71

Growth

11 metrics
Revenue growth YoY
+1.0%
Year over year
Net income growth YoY
-40.3%
Revenue (TTM)
$249.72M
Trailing 12 months
EPS growth YoY
-42.4%
Shares change YoY
+3.7%
Year over year · more shares
Revenue CAGR (3Y)
+4.4%
Revenue CAGR (5Y)
+13.2%
EPS CAGR (3Y)
+92.4%
EPS CAGR (5Y)
+13.6%
FCF CAGR (3Y)
+19.1%
FCF CAGR (5Y)
+2.4%

Quality

14 metrics
Return on equity
2.5%
Return on assets
1.1%
Debt / equity
0.4
Current ratio
1.8
EBITDA (TTM)
$37.06M
Free cash flow (TTM)
$52.87M
Quick ratio
1.3
Interest coverage
2.1
Net debt / EBITDA
—
Return on invested capital
5.1%
Trailing 12 months
Net cash
−$35.40M
Latest balance sheet
Cash & equivalents
$30.70M
Total assets
$419.22M
Total debt
$66.09M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$55.67M
Capital expenditures (TTM)
$2.80M
R&D (TTM)
$20.05M
SG&A (TTM)
—
Stock compensation (TTM)
$16.35M
R&D / revenue
8.0%
Stock compensation / revenue
6.5%

Ownership (13F)

9 metrics
13F filers
159
13F filer change QoQ
-2
Institutional ownership
89.9%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
48.9%
Private-fund adviser ownership
45.0%
Active holders' share change QoQ
+4.7%
Holder tenure
12.2
Price vs estimated holder cost
+10.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.5%

Short interest

3 metrics
Short interest
8.0%
Latest settlement · 3.7 days to cover
Days to cover
3.7d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
$102,321
Insider-sentiment score
79 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 724004 CUSIP 59064R109 13F (30d) 16 filings 16 filers Visit website Investor relations